Circulating CD3+CD8+ T Lymphocytes as Indicators of Disease Status in Patients With Early Breast Cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Circulating CD3+CD8+ cytotoxic T lymphocytes (CTL) and plasma chemokine (C-C motif) ligand 2 (CCL2) show potential as breast cancer biomarkers. Levels change with treatment and recurrence, indicating their role in disease management.
Area Of Science
- Immunology
- Oncology
- Biochemistry
Background
- Breast cancer is a significant global health concern.
- Identifying reliable biomarkers for diagnosis and monitoring is crucial.
- Understanding immune cell dynamics and molecular markers in breast cancer is ongoing.
Purpose Of The Study
- To investigate the role of circulating CD3+CD8+ T cells and plasma CCL2 as potential biomarkers in breast cancer.
- To assess the correlation of these markers with disease status, treatment, and recurrence.
Main Methods
- Quantification of circulating CD3+CD8+ T cell populations.
- Measurement of plasma chemokine (C-C motif) ligand 2 (CCL2) levels.
- Comparison of marker levels between breast cancer patients and healthy controls, and across different disease stages.
Main Results
- Circulating CD3+CD8+ T cell levels were lower in breast cancer patients compared to controls.
- These T cell levels increased post-treatment and decreased upon recurrence.
- Elevated plasma CCL2 levels were observed in breast cancer patients, distinguishing them from healthy individuals.
Conclusions
- Circulating CD3+CD8+ CTLs and plasma CCL2 are potential dual-purpose biomarkers for breast cancer.
- These markers may aid in diagnosis, treatment monitoring, and predicting recurrence.
- CCL2 and CD8+ T cells represent promising therapeutic targets in breast cancer management.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
